Dose escalation study of carboplatin-pemetrexed followed by maintenance pemetrexed for elderly patients with advanced nonsquamous nonsmall-cell lung cancer

Annals of Oncology

Volumn 24, Issue 4, 2013, Pages 980-985

  Tamiya, A ^a   Tamiya, M ^b   Shiroyama, T ^b   Kanazu, M ^a   Hirooka, A ^a   Tsuji, T ^a   Morishita, N ^b   Asami, K ^a   Suzuki, H ^b   Okamoto, N ^b   Okishio, K ^a   Kawaguchi, T ^a   Hirashima, T ^b   Atagi, S ^a   Kawase, I ^b  

^a NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

^b OSAKA GENERAL MEDICAL CENTER   (Japan)

Author keywords

Carboplatin; Elderly; Maintenance therapy; Nonsmall cell lung cancer; Pemetrexed

Indexed keywords

CARBOPLATIN; GEFITINIB; PEMETREXED;

ADVANCED NONSQUAMOUS NONSMALL CELL LUNG CANCER; AGED; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; SKIN TOXICITY; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; SURVIVAL RATE;

EID: 84875612797     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds544     Document Type: Article

References (26)

1. Gridelli C, Langer C, Maione P et al. Lung cancer in the elderly. J Clin Oncol 2007; 25: 1898-1907.
2. Gridelli C, Rossi A, Maione P. Challenges treating older non-small cell lung cancer patients. Ann Oncol 2008; 19: 109-113.
3. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311: 899-909.
4. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 1997; 15: 2996-3018.
5. Socinski MA, Crowell R, Hensing TE et al. Treatment of non-small cell lung cancer, stage IV: ACCP evidence based clinical practice guidelines (2nd edition). Chest 2007; 132(3 Suppl): 277S-289S.
6. Jennens RR, Giles GG, Fox RM. Increasing underrepresentation of elderly patients with advanced colorectal or non-small-cell lung cancer in chemotherapy trials. Intern Med J 2006; 36: 216-220.
7. Yee KW, Pater JL, Pho L et al. Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier? J Clin Oncol 2003; 21: 1618-1623.
8. Hutchins LF, Unger JM, Crowley JJ et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999; 341: 2061-2067.
9. Blanchard EM, Moon J, Hesketh PJ et al. Comparison of platinum-based chemotherapy in patients older and younger than 70 years: an analysis of Southwest Oncology Group Trials 9308 and 9509. J Thorac Oncol 2011; 6: 115-120.
10. Langer CJ, Manola J, Bernardo P et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 2002; 94: 173-181.
11. Lilenbaum RC, Herndon JE, II, List MA et al. Single-agent versus combination chemotherapy in advanced non-small cell lung cancer. The Cancer and Leukemia Group B (study 9730). J Clin Oncol 2005; 23: 190-196.
12. Langer CJ, Vangel M, Schiller J. Age-specific subanalysis of ECOG1594: fit elderly patients (70-80 yrs) with NSCLC do as well as younger patients (<70). Proc Am Soc Clin Oncol 2003; 22: 639. [Abstract 2571].
13. Belani CP, Fossella F. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for firstline treatment of advanced nonsmall cell lung carcinoma (TAX 326). Cancer 2005; 104: 2766-2774.
14. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 1999; 91: 66-72.
15. Frasci G, Lorusso V, Panza N et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small cell lung cancer. J Clin Oncol 2000; 18: 2529-2536.
16. Gridelli C, Perrone F, Gallo C et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003; 95: 362-372.
17. Kudoh S, Takeda K, Nakagawa K et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol 2006; 24: 3657-3663.
18. Quoix E, Zalcman G, Oster JP et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet 2011; 378: 1079-1088.
19. Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small cell lung cancer. J Clin Oncol 2008; 26: 3543-3551.
20. Scagliotti GV, Hanna N, Fossella FV et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009; 14: 253-263.
21. Paz-Ares L, de Marinis F, Dediu M et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-smallcell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol 2012; 13: 247-255.
22. Okamoto I, Takeda K, Daga H et al. Dose-escalation study of pemetrexed in combination with carboplatin followed by pemetrexed maintenance therapy for advanced non-small cell lung cancer. Lung Cancer 2010; 70: 168-173.
23. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
24. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
25. Ohe A, Ohashi Y, Kubota K et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 2007; 18: 317-323.
26. Aoe K, Nogami N, Okamoto H et al. Prospective multicenter clinical study of pemetrexed and carboplatin combination following by maintenance pemetrexed in chemo-naïve patients with non-squamous non-small cell lung cancer-initial analysis of induction period. 14th World Conference on Lung Cancer. Amsterdam, The Netherlands, July 2011; P3-P042.